Literature DB >> 2910184

Utility of near-total laryngectomy for supraglottic, pharyngeal, base-of-tongue, and other cancers.

L W DeSanto1, B W Pearson, K D Olsen.   

Abstract

This report emphasizes the utility of the near-total laryngectomy for those patients in whom conventional conservation surgery is an option but may be oncologically or physiologically unsafe. The near-total operation can be offered for supraglottic cancer, pharyngeal cancer, and, more commonly, primary glottic cancer with cord fixation. Its application is described for patients who are candidates for conventional conservation surgery but are compromised physiologically by age or poor general health and for patients in whom tumor extent would not permit safe conventional conservation surgery.

Entities:  

Mesh:

Year:  1989        PMID: 2910184     DOI: 10.1177/000348948909800102

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  4 in total

1.  Functional outcomes of patients with advanced pyriform sinus cancer treated with extended near-total laryngopharyngectomy and free fasciocutaneous flap reconstruction.

Authors:  Pei-Yin Wu; Yur-Ren Kuo; Seng-Feng Jeng; Cheng-Ming Hsu; Chih-Ying Su
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-26       Impact factor: 2.503

2.  Aspiration and speech shunt stenosis in near-total laryngectomy patients.

Authors:  C Y Su
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

3.  Functional utility and oncologic safety of near-total laryngectomy with tracheopharyngeal speech shunt in a Third World oncologic center.

Authors:  A M Shenoy; P K Plinkert; N Nanjundappa; S Premalata; G R Arunodhay
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

4.  Near total laryngectomy: the problems influencing functions and their solutions.

Authors:  Hamdi Cakli; Erkan Ozudogru; Emre Cingi; Cem Kecik; Kezban Gürbüz
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-03-05       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.